• 5 min read
• Published on 21 August 2025
Listen to article
6:16Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
Let’s be honest, the pharmaceutical world loves a blockbuster. For years, we’ve watched Novo Nordisk’s Wegovy become the go-to drug for weight loss, a genuine cultural phenomenon. But I think its latest trick is far more interesting for a savvy investor. The American regulators, the FDA, have just given it the nod to treat a nasty liver disease called MASH. This isn't just another feather in Novo's cap. It’s the starting pistol for a race that could create enormous value.
Until last week, the market for MASH treatments was worth precisely zero. Not a sausage. It’s a dreadful condition, progressing from a fatty liver to potentially fatal cirrhosis, and doctors could do little more than recommend a healthier lifestyle. Now, with one regulatory approval, a multi-billion pound market has just blinked into existence. Millions of people have the condition, and for the first time, there’s an approved medicine for it.
What’s truly significant here is the precedent. The FDA has essentially drawn a map for other drug developers. By granting an 'accelerated approval' based on improving liver scarring, they’ve told the industry what it needs to do to get a product over the line. This removes a huge amount of the guesswork and risk that has plagued liver disease research for decades. Suddenly, a field once considered a graveyard for promising drugs looks like fertile ground.
Of course, Novo Nordisk won’t have this playground to itself for long. A win this big always attracts competition, and several companies are already lining up at the gate, hoping to follow Wegovy’s blueprint. To me, this is where the real opportunity lies. You have companies like Madrigal Pharmaceuticals, which has a drug that tackles the problem from a slightly different angle but is aiming for the very same regulatory goalposts.
Then there are the more innovative players like 89bio, which is working on a treatment that could improve several metabolic factors at once, not just the liver. The science is complex, but the investment case is simple. These smaller, more focused companies could offer explosive growth if their trials succeed. Figuring out which of these contenders has the legs to go the distance is the real challenge, and it's a question at the heart of the Which Pharma Stocks Could Follow Wegovy's Success? investment theme.
This story is bigger than just one disease. Wegovy belongs to a class of drugs called GLP-1 agonists, originally designed for diabetes. Their success in weight loss and now liver disease shows they are becoming something of a Swiss Army knife for metabolic conditions. What’s next? Kidney disease? Heart failure? The possibilities are genuinely transformative.
For investors, this signals a fundamental shift. We are moving away from single-use drugs towards powerful platforms that can generate multiple streams of revenue. As global obesity rates continue their relentless climb, the demand for treatments that address the whole spectrum of related health problems is only going to grow. Companies that own these versatile drug platforms could be sitting on a goldmine. It’s a simple case of following the demographic and medical trends to their logical, and potentially very profitable, conclusion.
View the full Basket:Which Pharma Stocks Could Follow Wegovy's Success?
View the full Basket:Which Pharma Stocks Could Follow Wegovy's Success?
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article